Recent Innovations, Modifications, and Evolution of ACC/AHA Clinical Practice Guidelines: An Update for Our Constituencies: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
PMID: 30892927 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - March 20, 2019 Category: Cardiology Authors: Levine GN, O'Gara PT, Beckman JA, Al-Khatib SM, Birtcher KK, Cigarroa JE, de Las Fuentes L, Deswal A, Fleisher LA, Gentile F, Goldberger ZD, Hlatky MA, Joglar JA, Piano MR, Wijeysundera DN Tags: Circulation Source Type: research

Response by Siontis et al to Letter Regarding Article, "Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States".
Response by Siontis et al to Letter Regarding Article, "Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States". Circulation. 2019 Mar 19;139(12):1563-1564 Authors: Siontis KC, Zhang X, Schaubel DE, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK PMID: 30883218 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 19, 2019 Category: Cardiology Authors: Siontis KC, Zhang X, Schaubel DE, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK Tags: Circulation Source Type: research

Screening for High Lipoprotein(a).
PMID: 30883219 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 19, 2019 Category: Cardiology Authors: Thanassoulis G Tags: Circulation Source Type: research

Electrocardiographic Changes After Angioplasty of the Left Anterior Descending Coronary Artery.
bos-Gil MÁ PMID: 30883220 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 19, 2019 Category: Cardiology Authors: Playán-Escribano J, Martínez-Losas P, Cobos-Gil MÁ Tags: Circulation Source Type: research

Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)".
Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". Circulation. 2019 Mar 19;139(12):1559-1560 Authors: Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Lakdawala NK, Ware JS, Helms AS, Colan SD, Seidman CE, Olivotto I, SHaRe Investigators PMID: 30883221 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 19, 2019 Category: Cardiology Authors: Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Lakdawala NK, Ware JS, Helms AS, Colan SD, Seidman CE, Olivotto I, SHaRe Investigators Tags: Circulation Source Type: research

Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)".
Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". Circulation. 2019 Mar 19;139(12):1557-1558 Authors: Maron BJ, Rowin EJ, Maron MS PMID: 30883223 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 19, 2019 Category: Cardiology Authors: Maron BJ, Rowin EJ, Maron MS Tags: Circulation Source Type: research

Recommended Heart Failure Medications and Adverse Drug Reactions in Women.
PMID: 30883224 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 19, 2019 Category: Cardiology Authors: Bots SH, den Ruijter HM Tags: Circulation Source Type: research

Letter by Cheen Regarding Article, "Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States".
Letter by Cheen Regarding Article, "Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States". Circulation. 2019 Mar 19;139(12):1561-1562 Authors: Cheen MHH PMID: 30883225 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 19, 2019 Category: Cardiology Authors: Cheen MHH Tags: Circulation Source Type: research

Kindlin-2 Is Essential for Preserving Integrity of the Developing Heart and Preventing Ventricular Rupture.
PMID: 30883226 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 19, 2019 Category: Cardiology Authors: Zhang Z, Mu Y, Zhang J, Zhou Y, Cattaneo P, Veevers J, Peter AK, Manso AM, Knowlton KU, Zhou X, Evans SM, Ross RS, Chen J Tags: Circulation Source Type: research

Cardiovascular Effects of Treatment with the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
ash;tker HE, Wiggers H Abstract BACKGROUND: Myocardial utilization of 3-hydroxybutyrate (3-OHB) is increased in patients with heart failure and reduced ejection fraction (HFrEF). However, the cardiovascular effects of increased circulating P-3-OHB levels in these patients are unknown. Consequently, our aim was to modulate circulating 3-OHB levels in HFrEF patients and evaluate: 1) changes in cardiac output (CO), 2) a potential dose-response relationship between 3-OHB levels and CO, 3) the impact on myocardial external energy efficiency (MEE) and oxygen consumption (MVO2), and 4) whether the cardiovascular response...
Source: Circulation - March 19, 2019 Category: Cardiology Authors: Nielsen R, Møller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, Harms HJ, Frøkiær J, Eiskjaer H, Jespersen NR, Mellemkjaer S, Lassen TR, Pryds K, Bøtker HE, Wiggers H Tags: Circulation Source Type: research

Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients: The Prospective Randomized Controlled ICD2 Trial.
CONCLUSIONS: In a well-screened and well-treated population undergoing dialysis, prophylactic ICD therapy did not reduce the rate of SCD or all-cause mortality, which remained high. CLINICAL TRIAL REGISTRATION: URL: http://www.controlled-trials.com. Unique identifier: ISRCTN20479861. PMID: 30882234 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - March 18, 2019 Category: Cardiology Authors: Jukema JW, Timal RJ, Rotmans JI, Hensen LCR, Buiten MS, de Bie MK, Putter H, Zwinderman AH, van Erven L, Krol-van Straaten MJ, Hommes N, Gabreëls B, van Dorp W, van Dam B, Herzog CA, Schalij MJ, Rabelink TJ, ICD2 Trial Investigators Tags: Circulation Source Type: research

Long-Term Consumption of Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Mortality in US Adults.
PMID: 30882235 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - March 18, 2019 Category: Cardiology Authors: Malik VS, Li Y, Pan A, De Koning L, Schernhammer E, Willett WC, Hu FB Tags: Circulation Source Type: research

The Serendipitous Story of SGLT2 Inhibitors in Heart Failure: New Insights from DECLARE-TIMI 58.
Abstract Diabetes intersects with cardiovascular disease at every level. While there has been much focus on understanding atherosclerotic complications, less well appreciated is the relationship between diabetes and heart failure. In addition to being a key and independent risk factor for the development of heart failure,1 diabetes is also one of the most important adverse prognostic factors in those with established heart failure with either reduced or preserved ejection fraction. 1,2 Diabetes is associated with a high prevalence of unrecognized left ventricular diastolic and systolic dysfunction, and accelerates...
Source: Circulation - March 18, 2019 Category: Cardiology Authors: Verma S, McMurray JJV Tags: Circulation Source Type: research

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
t SD Abstract BACKGROUND: In DECLARE-TIMI 58, the sodium glucose co-transporter 2 inhibitor (SGLT2i) dapagliflozin reduced the composite endpoint of cardiovascular (CV) death/ hospitalization for heart failure (HHF) in a broad population of patients with T2DM. However, the impact of baseline left ventricular ejection fraction (EF) on the clinical benefit of SGLT2i is unknown. METHODS: In the DECLARE-TIMI 58 trial, baseline HF status was collected from all patients and EF where available. HF with reduced EF (HFrEF) was defined as EF
Source: Circulation - March 18, 2019 Category: Cardiology Authors: Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wivio Tags: Circulation Source Type: research

Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial.
CONCLUSIONS: Patients with T2DM and prior MI are at high risk of MACE and CV death/HHF. Dapagliflozin appears to robustly reduce the risk of both composite outcomes in these patients. Future studies should aim to confirm the large clinical benefits with SGLT2i we observed in patients with prior MI. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov Unique Identifier: NCT01730534. PMID: 30882239 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - March 18, 2019 Category: Cardiology Authors: Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD Tags: Circulation Source Type: research

Representation of Patients with Cardiovascular Disease in Pivotal Cancer Clinical Trials.
Abstract Cardiovascular disease (CVD) is increasingly common among new cancer patients, with a reported prevalence near 30% at diagnosis.1,2 Cancer patients with concurrent CVD have poorer outcomes than those without CVD.1-3 Despite the high prevalence of CVD and its prognostic significance, there is limited evidence to guide the care of this increasing population. One possible explanation may be the exclusion of CVD patients from clinical trials.3 In the US, pivotal clinical trials of anticancer drugs are reviewed by the Food and Drug Administration (FDA) for adequate representation and safety prior to approval a...
Source: Circulation - March 18, 2019 Category: Cardiology Authors: Bonsu J, Charles L, Guha A, Awan F, Woyach J, Yildiz V, Wei L, Jneid H, Addison D Tags: Circulation Source Type: research

The New 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.
Abstract Much of the cardiovascular disease burden and mortality can be traced back to four adverse health behaviors (smoking, poor diet, elevated body mass index, sedentary lifestyle) and three major risk factors (hypercholesterolemia, hypertension, diabetes). Ideal cardiovascular health defined as having all seven factors at goal is very rare among US adults. It is estimated that 87% of middle-aged US adults and 95% of individuals ≥60 years old meet ≤4 of these health metrics.1 Detailed guidelines are available that discuss cardiovascular risk assessment, lifestyle management, and treatment of individual r...
Source: Circulation - March 17, 2019 Category: Cardiology Authors: Bittner VA Tags: Circulation Source Type: research

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary.
ian B PMID: 30879339 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - March 17, 2019 Category: Cardiology Authors: Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Virani SS, Williams KA, Yeboah J, Ziaeian B Tags: Circulation Source Type: research

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.
ian B PMID: 30879355 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - March 17, 2019 Category: Cardiology Authors: Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Virani SS, Williams KA, Yeboah J, Ziaeian B Tags: Circulation Source Type: research

Practice Variation in Anticoagulation Prescription and Outcomes after Device-Detected Atrial Fibrillation: Insights from the Veterans Health Administration.
CONCLUSIONS: Among Veterans with CIEDs, device-detected AF is common. There is large practice variation in 90-day OAC initiation after new device-detected AF with low rates of treatment overall, even for episodes>24 hours. The strongest association of OAC with reduction in stroke was observed after device-detected AF>24 hours. Randomized trials are needed to confirm these observational findings. PMID: 30880434 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - March 17, 2019 Category: Cardiology Authors: Perino AC, Fan J, Askari M, Heidenreich PA, Keung E, Raitt MH, Piccini JP, Ziegler PD, Turakhia MP Tags: Circulation Source Type: research

Device-Detected Atrial Fibrillation: Evidencing the Knowledge Gap.
Abstract Stroke is a devastating complication of atrial fibrillation (AF) the odds of which can be reduced by use of oral anticoagulation based on the stroke risk score.1,2 Patients with asymptomatic clinical AF have a similar stroke risk as patients with symptomatic clinical AF.3 Thus far, electrocardiographic- (ECG) or Holter monitor-detected AF is a prerequisite before use of oral anticoagulation,1,2 because the guideline recommendations are based on studies that included only ECG- or Holter-detected AF ('clinical' AF).1,2 In the past decades increasing number of cardiac implantable electronic devices (CIED) ha...
Source: Circulation - March 17, 2019 Category: Cardiology Authors: Mulder BA, van Gelder IC, Rienstra M Tags: Circulation Source Type: research

Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial.
We report 6-month results following the addition of a recommended standardized stepped-care antihypertensive treatment (SSAHT) to the randomized endovascular procedure under continued blinding to initial treatment. METHODS: Patients with a daytime ambulatory BP greater ≥135/85 mmHg and
Source: Circulation - March 17, 2019 Category: Cardiology Authors: Azizi M, Schmieder RE, Mahfoud F, Weber M, Daemen J, Lobo MD, Sharp ASP, Bloch MJ, Basile JN, Wang Y, Saxena M, Lurz P, Rader F, Sayer JW, Fisher NDL, Fouassier D, Barman NC, Reeve-Stoffer H, McClure C, J Kirtane A Tags: Circulation Source Type: research

Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program.
al B Abstract Patients with type 2 diabetes mellitus are at high risk of developing heart failure (HF).1 Sodium glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated, in large scale trials, to reduce the risk of HF events in patients with type 2 diabetes deemed to be at high risk based on established cardiovascular disease or multiple risk factors.2-4 However, it is unclear whether benefits are experienced across the broad spectrum of HF patients that includes those with preserved (HFpEF) as well as reduced ejection fraction (HFrEF). PMID: 30882240 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - March 17, 2019 Category: Cardiology Authors: Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B Tags: Circulation Source Type: research

Human Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Breast Cancer Patients.
CONCLUSIONS: Our results indicate that alterations in cellular metabolic pathways in cardiomyocytes could be a key mechanism underlying the development of cardiac dysfunction following trastuzumab therapy; therefore, targeting the altered metabolism may be a promising therapeutic approach for trastuzumab-induced cardiac dysfunction. PMID: 30866650 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - March 14, 2019 Category: Cardiology Authors: Kitani T, Ong SG, Lam CK, Rhee JW, Zhang JZ, Oikonomopoulos A, Ma N, Tian L, Lee J, Telli ML, Witteles RM, Sharma A, Sayed N, Wu JC Tags: Circulation Source Type: research

New and Emerging Tobacco Products and the Nicotine Endgame: The Role of Robust Regulation and Comprehensive Tobacco Control and Prevention: A Presidential Advisory From the American Heart Association.
Abstract The advent of new tobacco products such as electronic cigarettes and the dramatic rise in their use, especially by adolescents and young adults, are significant public health concerns. Electronic cigarettes have become the most popular tobacco products for youth and adolescents in the United States and are attracting youth to new avenues for nicotine addiction. Although these products may have benefit by helping some smokers quit or to move to a less harmful product, the long-term health effects of these products and the net public health effect associated with their use remain unclear and widely debated....
Source: Circulation - March 13, 2019 Category: Cardiology Authors: Bhatnagar A, Whitsel LP, Blaha MJ, Huffman MD, Krishan-Sarin S, Maa J, Rigotti N, Robertson RM, Warner JJ Tags: Circulation Source Type: research

Abdominal Aortic Aneurysm Screening Is Safe yet Lacks Effectiveness.
PMID: 30855994 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 12, 2019 Category: Cardiology Authors: Arnaoutakis DJ, Upchurch GR Tags: Circulation Source Type: research

Letter by Long et al Regarding Article, "Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease".
Letter by Long et al Regarding Article, "Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease". Circulation. 2019 Mar 12;139(11):1467-1468 Authors: Long M, Ye Z, Li L PMID: 30855995 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 12, 2019 Category: Cardiology Authors: Long M, Ye Z, Li L Tags: Circulation Source Type: research

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
PMID: 30855996 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 12, 2019 Category: Cardiology Authors: Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, Butler J Tags: Circulation Source Type: research

The Need to Improve Derivation and Description of Algorithms to Rule-Out Patients With Possible Myocardial Infarction.
PMID: 30855997 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 12, 2019 Category: Cardiology Authors: Pickering JW Tags: Circulation Source Type: research

Large Trial Finds Yoga Boosts Quality of Life and Return to Activity and Adds to Emerging Evidence for Rehabilitation Alternatives.
PMID: 30855998 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 12, 2019 Category: Cardiology Authors: Kuehn BM Tags: Circulation Source Type: research

Sacubitril/Valsartan to Reduce Secondary Mitral Regurgitation.
PMID: 30855999 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 12, 2019 Category: Cardiology Authors: Mullens W, Martens P Tags: Circulation Source Type: research

Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
Abstract Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome with an increasingly recognized heterogeneity in pathophysiology. Exercise intolerance is the hallmark of HFpEF and appears to be caused by both cardiac and peripheral abnormalities in the arterial tree and skeletal muscle. Mitochondrial abnormalities can significantly contribute to impaired oxygen utilization and the resulting exercise intolerance in HFpEF. We review key aspects of the complex biology of this organelle, the clinical relevance of mitochondrial function, the methods that are currently available to assess mitochond...
Source: Circulation - March 12, 2019 Category: Cardiology Authors: Kumar AA, Kelly DP, Chirinos JA Tags: Circulation Source Type: research

Letter by Pal Regarding Article, "Clinical Outcome of Degenerative Mitral Regurgitation: Critical Importance of Echocardiographic Quantitative Assessment in Routine Practice".
Letter by Pal Regarding Article, "Clinical Outcome of Degenerative Mitral Regurgitation: Critical Importance of Echocardiographic Quantitative Assessment in Routine Practice". Circulation. 2019 Mar 12;139(11):1463-1464 Authors: Pal N PMID: 30856001 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 12, 2019 Category: Cardiology Authors: Pal N Tags: Circulation Source Type: research

A Peculiar Wide Complex Tachycardia.
PMID: 30856002 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 12, 2019 Category: Cardiology Authors: Butt K, Ambati S Tags: Circulation Source Type: research

Response by Enriquez-Sarano and Antoine to Letter Regarding Article, "Clinical Outcome of Degenerative Mitral Regurgitation: Critical Importance of Echocardiographic Quantitative Assessment in Routine Practice".
Response by Enriquez-Sarano and Antoine to Letter Regarding Article, "Clinical Outcome of Degenerative Mitral Regurgitation: Critical Importance of Echocardiographic Quantitative Assessment in Routine Practice". Circulation. 2019 Mar 12;139(11):1465-1466 Authors: Enriquez-Sarano M, Antoine C PMID: 30856003 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 12, 2019 Category: Cardiology Authors: Enriquez-Sarano M, Antoine C Tags: Circulation Source Type: research

Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association.
Abstract Cardiorenal syndrome encompasses a spectrum of disorders involving both the heart and kidneys in which acute or chronic dysfunction in 1 organ may induce acute or chronic dysfunction in the other organ. It represents the confluence of heart-kidney interactions across several interfaces. These include the hemodynamic cross-talk between the failing heart and the response of the kidneys and vice versa, as well as alterations in neurohormonal markers and inflammatory molecular signatures characteristic of its clinical phenotypes. The mission of this scientific statement is to describe the epidemiology and pat...
Source: Circulation - March 11, 2019 Category: Cardiology Authors: Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W, Ronco C, Tang WHW, McCullough PA, American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology Tags: Circulation Source Type: research

Water Pipe (Hookah) Smoking and Cardiovascular Disease Risk: A Scientific Statement From the American Heart Association.
The objectives of this statement are to describe the design and operation of water pipes and their use patterns, to identify harmful and potentially harmful constituents in water pipe smoke, to document the cardiovascular risks of water pipe use, to review current approaches to water pipe smoking cessation, and to offer guidance to healthcare providers for the identification and treatment of individuals who smoke tobacco using water pipes. PMID: 30845826 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - March 8, 2019 Category: Cardiology Authors: Bhatnagar A, Maziak W, Eissenberg T, Ward KD, Thurston G, King BA, Sutfin EL, Cobb CO, Griffiths M, Goldstein LB, Rezk-Hanna M, American Heart Association Behavioral Change for Improving Health Factors Committee of the Council on Lifestyle and Cardiometab Tags: Circulation Source Type: research

A New Beginning for Triglyceride Lowering Therapies.
Abstract The cardiovascular community has been debating for decades whether to treat mild-tomoderate hypertriglyceridemia. Results of the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)1 position this controversy as front matter for deliberation. For lipid experts, dominating the discourse will be the strength of experimental evidence, mechanism of benefit, identification of treatment response parameters, and prioritizing treatment options. For the practitioner, the question ultimately will be whether potential gains are worth the disruption to clinical care that accompanies ...
Source: Circulation - March 6, 2019 Category: Cardiology Authors: Pradhan AD Tags: Circulation Source Type: research

Letter by Kuwabara Regarding Article, "Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study".
Letter by Kuwabara Regarding Article, "Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study". Circulation. 2019 Mar 05;139(10):1348-1349 Authors: Kuwabara M PMID: 30830802 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 5, 2019 Category: Cardiology Authors: Kuwabara M Tags: Circulation Source Type: research

Correction to: Platelet Protein Disulfide Isomerase Promotes Glycoprotein Ib α-Mediated Platelet-Neutrophil Interactions Under Thromboinflammatory Conditions.
Correction to: Platelet Protein Disulfide Isomerase Promotes Glycoprotein Ibα-Mediated Platelet-Neutrophil Interactions Under Thromboinflammatory Conditions. Circulation. 2019 Mar 05;139(10):e529 Authors: PMID: 30830803 [PubMed - in process] (Source: Circulation)
Source: Circulation - March 5, 2019 Category: Cardiology Tags: Circulation Source Type: research

The Long Non-Coding RNA CPR Regulates Cardiomyocyte Proliferation and Cardiac Repair.
CONCLUSIONS: Together, our findings identified that CPR is a suppressor of cardiomyocyte proliferation, and it indicates that lncRNA(s) take parts in the regulation of cardiomyocyte proliferation and cardiac repair. Our study provides an lncRNA-based therapeutic strategy for effective cardiac repair and regeneration. PMID: 30832495 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - March 5, 2019 Category: Cardiology Authors: Ponnusamy M, Liu F, Zhang YH, Li RB, Zhai M, Liu F, Zhou LY, Liu CY, Yan KW, Dong YH, Wang M, Qian LL, Shan C, Xu S, Wang Q, Zhang YH, Li PF, Zhang J, Wang K Tags: Circulation Source Type: research

Fibroblast Primary Cilia are Required for Cardiac Fibrosis.
CONCLUSIONS: Cardiac fibroblasts in the neonatal and adult heart harbor a primary cilium. This organelle and its requisite signaling protein, PC1, are required for critical elements of fibrogenesis, including TGF-β1 SMAD3 activation, production of extracellular matrix proteins, and cell contractility. Together, these findings point to a pivotal role of this organelle, and PC1, in disease-related pathological cardiac remodeling, and suggest that some of the cardiovascular manifestations of autosomal dominant polycystic kidney disease derive directly from myocardium-autonomous abnormalities. PMID: 30818997 [PubMed ...
Source: Circulation - March 1, 2019 Category: Cardiology Authors: Villalobos E, Criollo A, Schiattarella GG, Altamirano F, French KM, May HI, Jiang N, Nguyen NUN, Romero D, Roa JC, García L, Diaz-Araya G, Morselli E, Ferdous A, Conway SJ, Sadek HA, Gillette TG, Lavandero S, Hill JA Tags: Circulation Source Type: research

Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion: The DECISION-CTO Trial.
CONCLUSIONS: CTO-PCI was feasible with high success rates. There was no difference in the incidence of major adverse cardiovascular events with CTO PCI vs. no CTO-PCI, but the study was limited by low power for clinical endpoints and high crossover rates between groups. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov Unique Identifier: NCT01075051. PMID: 30813758 [PubMed - as supplied by publisher] (Source: Circulation)
Source: Circulation - February 28, 2019 Category: Cardiology Authors: Lee SW, Lee PH, Ahn JM, Park DW, Yun SC, Han S, Kang H, Kang SJ, Kim YH, Lee CW, Park SW, Hur SH, Rha SW, Her SH, Choi SW, Lee BK, Lee NH, Lee JY, Cheong SS, Kim MH, Ahn YK, Lim SW, Lee SG, Hiremath S, Santoso T, Udayachalerm W, Cheng JJ, Cohen DJ, Murama Tags: Circulation Source Type: research

Substantial Cardiovascular Morbidity in Adults with Lower-Complexity Congenital Heart Disease.
Abstract BACKGROUND: Although lower-complexity cardiac malformations constitute the majority of adult congenital heart disease (ACHD), the long-term risks of adverse cardiovascular events and relationship with conventional risk factors in this population are poorly understood. We aimed to quantify the risk of adverse cardiovascular events associated with lower-complexity ACHD that is unmeasured by conventional risk factors. METHODS: A multi-tiered classification algorithm was used to select individuals with lower-complexity ACHD and individuals without ACHD for comparison amongst>500,000 British adults in ...
Source: Circulation - February 28, 2019 Category: Cardiology Authors: Saha P, Potiny P, Rigdon J, Morello M, Tcheandjieu C, Romfh A, Fernandes SM, McElhinney DB, Bernstein D, Lui GK, Shaw GM, Ingelsson E, Priest JR Tags: Circulation Source Type: research

Cumulative Psychosocial Stress and Ideal Cardiovascular Health in Older Women: Data by Race/Ethnicity.
rt MA Abstract BACKGROUND: Research implicates acute and chronic stressors in racial/ethnic health disparities, but the joint impact of multiple stressors on racial/ethnic disparities in cardiovascular health is unknown. METHODS: In 25,062 women (N: White: 24,053; Hispanic: 256; Black: 440; Asian: 313) participating in the Women's Health Study (WHS) follow-up cohort, we examined the relationship between cumulative psychosocial stress (CPS) and ideal cardiovascular health (ICH), as defined by the American Heart Association Strategic 2020 goals. This health metric includes smoking, body mass index, physical act...
Source: Circulation - February 28, 2019 Category: Cardiology Authors: Burroughs-Peña MS, Mbassa RS, Slopen NB, Williams DR, Buring J, Albert MA Tags: Circulation Source Type: research

DNA Damage Response Mediates Pressure Overload-Induced Cardiomyocyte Hypertrophy.
PMID: 30802166 [PubMed - in process] (Source: Circulation)
Source: Circulation - February 26, 2019 Category: Cardiology Authors: Nakada Y, Nhi Nguyen NU, Xiao F, Savla JJ, Lam NT, Abdisalaam S, Bhattacharya S, Mukherjee S, Asaithamby A, Gillette TG, Hill JA, Sadek HA Tags: Circulation Source Type: research

Antithrombotic Therapy for Stroke Prevention.
PMID: 30802167 [PubMed - in process] (Source: Circulation)
Source: Circulation - February 26, 2019 Category: Cardiology Authors: Hankey GJ Tags: Circulation Source Type: research

Reexamining the Open-Vein Hypothesis for Acute Deep Venous Thrombosis.
PMID: 30802168 [PubMed - in process] (Source: Circulation)
Source: Circulation - February 26, 2019 Category: Cardiology Authors: Nathan AS, Giri J Tags: Circulation Source Type: research

Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients.
PMID: 30802169 [PubMed - in process] (Source: Circulation)
Source: Circulation - February 26, 2019 Category: Cardiology Authors: Nafee T, Gibson CM, Yee MK, Kerneis M, Daaboul Y, Korjian S, Chi G, Kalayci A, Afzal MK, Kazmi H, Datta S, AlKhalfan F, Hernandez AF, Hull RD, Harrington RA, Cohen AT, Goldhaber SZ Tags: Circulation Source Type: research

Correction to: Prevention of Cardiogenic Shock After Acute Myocardial Infarction.
Authors: PMID: 30802170 [PubMed - in process] (Source: Circulation)
Source: Circulation - February 26, 2019 Category: Cardiology Tags: Circulation Source Type: research